Ikena Oncology, Inc. (IMA): Price/Earnings to Growth Multiple
ImageneBio Inc (IMA) maintains a high reputation for developing biomarker-based cancer treatments. The PEG ratio visualizes capital efficiency, with the 0.00 mark recording this metric. The company's technologies are based on identifying the molecular vulnerabilities of tumors. Meanwhile, the financial balance sheet remains stable, ensuring full fulfillment of all current obligations.
Analytical breakdowns for ImageneBio Inc (IMA)
- price and consensus price forecast:
- stock exchange capitalization data:
- book value of equity indicators:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
IMA - Net Profit|Projected Net Profit ImageneBio Inc|IMA - P/E Multiple|Projected Price to Earnings Ratio ikenaoncology.com|IMA - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Ikena Oncology, Inc.|IMA - Operating profit EBITDA|Net earnings per one share for the last twelve months Ikena Oncology|IMA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months ikenaoncology.com|IMA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year ImageneBio Inc
General company analysis:IMA, ImageneBio
The PEG ratio distinguishes a genuine investment trend from a short-term speculative spike. The formula compares a stock's market value with its earnings growth rate, identifying an undervalued asset when the value falls below one. By analyzing the average PEG, an investor gains an objective view of value dynamics relative to business expansion. For ImageneBio Inc (IMA), this indicator is critical due to its high concentration in immuno-oncology. Early-stage pipeline risks here are mitigated by support from venture capital funds.
Competitors of ImageneBio Inc
Growth-Adjusted Market Cap to Net Income argenx N.V.|Price/Earnings to Growth Ratio BioNTech Group BNTX|ABVX - Price/Earnings to Growth Multiple|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|IMVT (Immunovant) - Price/Earnings to Growth Multiple|Kiniksa Pharmaceuticals, Ltd. (KNSA) - PEG Multiple|Price/Earnings to Growth Ratio Grifols Group|Growth-Adjusted P/E Ratio ADPT (Adaptive Biotechnologies Inc.)|PEG Multiple CLDX|AUPH - Price to Earnings Adjusted for Growth Rate|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Growth-Adjusted Market Cap to Net Income Vera Therapeutics Inc (VERA)|DNTH - Price/Earnings to Growth Ratio|Pharvaris Pharma (PHVS) - Price/Earnings to Growth Multiple|ABCL: PEG Multiple|tourmalinebio.com (TRML) - PEG Multiple|PGEN (Precigen) - PEG Multiple|PHAR - Price to Net Income Growth Ratio|PEG Multiple NKTR|UPB - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Zenas Biopharma Inc ZBIO|IMNM: Growth-Adjusted P/E Ratio|Gossamer Bio - PEG Multiple|Price to Earnings Adjusted for Growth Rate KalVista Pharma|SEPN: PEG Multiple|PVLA (Pieris Corp) - Price/Earnings to Growth Ratio|SVRA (Savara Inc.) - PEG Multiple|rigel.com (RIGL) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio AnaptysBio (ANAB)|ATXS - Price to Earnings Adjusted for Growth Rate|enGene Bio - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio RAPT|Aerovate - PEG Multiple|Growth-Adjusted Market Cap to Net Income aclaristx.com ACRS|Kyverna Therapeutics, Inc. (KYTX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio TLSA|CABA (Cabaletta Bio, Inc) - PEG Multiple|Price/Earnings to Growth Multiple Ventyx Biosciences, Inc (VTYX)|PEG Multiple THTX|Growth-Adjusted Market Cap to Net Income avalotx.com|Price/Earnings to Growth Ratio Eledon Pharmaceuticals, Inc. ELDN|AGEN - Price/Earnings to Growth Multiple|Climb Bio, Inc. - PEG Multiple|ZURA - PEG Multiple|aTyr Pharma, Inc. (ATYR) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio ADAG (Adagene Inc.)|STTK (Shattuck Labs Inc) - PEG Multiple|EQ: Growth-Adjusted Payback Ratio|PEG Multiple CNTB|PEG Multiple immunic-therapeutics.com (IMUX)|Price/Earnings to Growth Ratio Atara Bio ATRA|Growth-Adjusted Payback Ratio IFRX|XFOR - Price/Earnings to Growth Ratio|Adicet Bio (ACET) - Price/Earnings to Growth Multiple|CELU: PEG Multiple|INmune Bio Corporation (INMB) - PEG Multiple|Price/Earnings to Growth Multiple BRNS|KZR: Growth-Adjusted Payback Ratio|PEG Multiple SABS|Growth-Adjusted Market Cap to Net Income Akari Therapeutics PLC|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Price/Earnings to Growth Multiple|GOVX - Price/Earnings to Growth Ratio|edesabiotech.com (EDSA) - Price/Earnings to Growth Multiple|IBIO (iBio) - Price/Earnings to Growth Multiple|Carisma Therapeutics Inc. (CARM) - PEG Multiple|Price/Earnings to Growth Ratio XTL Biopharmaceuticals, Ltd.|Growth-Adjusted P/E Ratio BOLT (Bolt Bio)|PEG Multiple HCWB|APVO - Price to Earnings Adjusted for Growth Rate|PEG Multiple AIM (AIM ImmunoTech)|Growth-Adjusted Market Cap to Net Income Aditxt Inc. (ADTX)|GRI - Price/Earnings to Growth Ratio|XORTX Corp (XRTX) - Price/Earnings to Growth Multiple|HIND: PEG Multiple|revbiosciences.com (REVB) - PEG Multiple|INDP (Indaptus Therapeutics, Inc.) - PEG Multiple|SCNI - Price to Net Income Growth Ratio|PEG Multiple CALI|AFMD - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Allakos ALLK|HOOK: Growth-Adjusted P/E Ratio|IGM Bio - PEG Multiple|Price to Earnings Adjusted for Growth Rate iTeos Therapeutics Inc|OCEA: PEG Multiple|TCBP (TC BioPharm Ltd) - Price/Earnings to Growth Ratio|THRD (Third Harmonic Bio) - PEG Multiple
